Antineovascularisation Agents
- Name
- Antineovascularisation Agents
- Accession Number
- DBCAT002389
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Verteporfin A benzoporphyrin derivative used to treat pathological myopia, ocular histoplasmosis, and choroidal neovascularization in macular degeneration. Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Pegaptanib A selective vascular endothelial growth factor (VEGF) antagonist used for the treatment of neovascular (wet) age-related macular degeneration. Aflibercept A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer Anecortave Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension). Brolucizumab An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Abicipar Pegol Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration. Faricimab An IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema. - Drugs & Drug Targets